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The expression of caveolin-1 (CAV1) in both tumor cell and cancer-associated fibroblasts (CAFs) has been found to correlate with
tumor aggressiveness in different epithelial tumor entities, whereas less is known for caveolin-2 (CAV2). The aim of this study was
to investigate the clinicopathological significance and prognostic value of stromal CAV1 and CAV2 expression in lung cancer. The
expression of these two genes was investigated at protein level on a tissue microarray (TMA) consisting of 161 primary tumor
samples. 50.7% of squamous cell lung cancer (SCC) tumors showed strong expression of CAV1 in the tumor-associated stromal
cells, whereas only 15.1% of adenocarcinomas (AC) showed a strong CAV1 expression (p < 0 01). A strong CAV2 stromal
expression was found in 46.0% of the lung tumor specimens, with no significant difference between the subtypes. Neither CAV1
nor CAV2 stromal expression was associated with any other clinicopathological factor including survival. When the stromal
expression in matched primary tumors and lymph node metastases was compared, both CAV1 and CAV2 expressions were
frequently found lost in the corresponding stroma of the lymph node metastasis (40.6%, p = 0 003 and 38.4%, p = 0 001, resp.).
Loss of stromal CAV2 in the lymph node metastases was also significantly associated with earlier death (p = 0 011). In
conclusion, in contrast to the expression patterns in the tumor tissue of lung cancer, stromal expression of CAV1 in primary
tumors was not associated with clinical outcome whereas the stromal expression of especially CAV2 in the metastatic lymph
nodes could be associated with lung cancer pathogenesis.
1. Introduction
Caveolin-1 (CAV1) and caveolin-2 (CAV2) are integral
membrane proteins found in the outer cell membrane
called caveolae and in other intracellular membranes of
the endoplasmic reticulum, Golgi apparatus, and transport
vesicles [1, 2]. Both proteins are also found as soluble pro-
teins [2, 3] and are expressed in fibroblasts, endothelial
cells, lipocytes, and in type I pneumocytes [4, 5]. They
are involved in various mechanisms like membrane traffick-
ing as well as signal transduction and gene regulation of cell
growth and apoptosis [2, 6–8]. Caveolins have also been
implicated in many processes involved in cancer initiation
and metastasis [6, 9]. It has been shown that CAV1 may
possess both tumor suppressing and oncogenic functions,
depending on progress and tumor type [10]. In early stages
of the disease, CAV1 has been shown to function mainly as
a tumor suppressor, whereas at later stages, CAV1 expression
has been associated with progression and metastasis [6, 11].
The role of CAV2 in carcinogenesis is less well documented.
In our previous study, we analyzed the expression of both
proteins in primary tumors from lung cancer patients [4].
Loss of CAV1 protein expression was detected in 48% of
the tumors, whereas 28% of the tumors did not express
CAV2. CAV2 protein expression correlated with shorter sur-
vival whereas no such association was found for CAV1 [4].
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Nowadays, it is well-known that the tumor microenvi-
ronment plays a critical role in determining tumor initiation
and progression [12]. The tumor microenvironment consists
among others of stromal cells such as cancer-associated
fibroblasts, which serve under normal physiological condi-
tions as a barrier to prevent malignant transformation. How-
ever, during neoplastic transformation, the tumor-associated
stroma may enable tumor progression and metastasis in
response to molecular signals derived from the tumor cells
[13, 14]. The level of expressed CAV1 in cancer-associated
stroma has been shown to be associated with clinical param-
eters such as survival time. The absence of stromal CAV1 in
breast cancer was shown in numerous studies to be associ-
ated with early disease recurrence, advanced tumor stage
and lymph node metastases, increased distant metastasis,
and poor survival [15–19]. Loss of stromal CAV1 expression
has also been correlated with poor prognosis in the malig-
nant melanoma; esophageal and oral squamous cell carci-
noma; and gastric, prostate, pancreatic, and colorectal
cancer [10, 20–29]. In malignant pleural mesothelioma and
in tongue squamous cell carcinoma, an inverse correlation
was found between CAV1 stromal expression and survival
[30, 31]. The role of stromal CAV1 in the lung cancer is
controversial: in two studies with small case numbers
(n = 37 and n = 62), the stromal CAV1 expression was corre-
lated with improved survival [32, 33], whereas in a large
study (n = 412), the expression of stromal CAV1 in lung
adenocarcinoma (AC) was associated with a significantly
worse overall survival [34]. Only few data are found regard-
ing the association of stromal CAV2 with tumor progression.
The expression of CAV2 was shown to be raised in the
stroma with the degree of invasivity of breast cancer [32].
Another study showed in thyroid cancer a correlation
between stromal CAV2 expression with larger tumors,
tumors with bilateral lobe involvement, and higher number
of lymph node metastases (>8) [33].
To explore the relationship between stromal CAV1 and
CAV2 expression and lung cancer, we analyzed expression
for both proteins in stromal cells of the primary tumor as well
as lymph nodes of human lung cancer tissues placed on
TMAs. To our knowledge, the putative role of stromal
CAV2 expression on tumor behavior in lung cancer has not
been reported previously.
2. Methods
2.1. Tissue Microarrays and Patient Samples. Two different
tissue microarrays (TMA) were used. The results of tumor
caveolin expression from first TMA have already been
reported previously [4]. Here, four replicates of tumor tissue
of 1.0mm in diameter from minimum two different paraffin
blocks in each case were placed on TMA blocks in addition to
two samples representing normal central bronchus and
peripheral lung. Altogether, tumor samples from 161 patients
were placed on these TMA. Corresponding lymph node
metastases (two replicates) were also placed on the TMAs
from 47 patients. The second TMA consisted of 13-matched
primary tumor tissues and matched lymph node metasta-
ses as well as 4 additional unmatched lymph node samples
(two replicates) [34]. Evaluable results of tumor-related
stromal expression were obtained from 147 patients for
CAV1 and 150 patients for CAV2. 68 of the 150 primary
tumor samples were classified as squamous cell carcinoma
(SCC), 51 as AC, five as AC-SCC, 10 as large-cell lung
carcinoma (LCLC), eight as small-cell lung carcinoma
(SCLC), four as large-cell neuroendocrine carcinoma
(LCNEC), and three as giant cell carcinoma of the lung
(GCCL). All patients were personally interviewed, and
their consent to take part in the study and to use their tis-
sue was obtained. The study protocol has been approved
by the Ethical Review Board for Research in Occupational
Health and Safety (75/E2/2001).
2.2. CAV1 and CAV2 Immunohistochemistry. The immuno-
histochemistry was published before [4]. Briefly, TMA
sections (4μm) were deparaffinized and rehydrated in a
series of graded alcohol. The sections were pretreated for
antigen retrieval in a microwave oven in Tris-EDTA
buffer (pH9.0). The antibody staining was performed in
a TechMate Horizon immunostainer (DAKO ChemMate,
Denmark) using primary mouse monoclonal anti-caveolin-
1 (clone 2297) and anti-caveolin-2 (clone 65) antibodies
(BD Transduction Laboratories, San Jose, CA, USA). Nega-
tive controls were performed by replacing the primary
antibody with buffer [4].
2.3. Scoring and Statistical Analyses of IHC Results. Each
sample on the TMA was analyzed by two independent inves-
tigators (Wladimir Gerstenberger and Stefan Steurer). The
percentage of tumor cells stained positive and the intensity
of staining was recorded from each sample. An arbitrary scale
of 0, 1, and 2 was used. A value of zero was given when less
than 15% of the cells were positive, 1 for a weak homog-
enous staining (15%–60%), and 2 for an intense (high)
staining (60%–100%) corresponding to the staining of stro-
mal lung tissue was present.
Chi-square or Fisher’s exact test was used to analyze the
correlation between caveolin expression status and patients’
clinical parameters. Patient groups were combined if the
group size was below 10 cases. Survival analyses were per-
formed using the Kaplan-Mayer method for survival curves,
and survival differences were analyzed with log-rank-test
using the SPSS version 20 software.
3. Results
3.1. Caveolin 1 Expression in Tumor Stroma. In our study, the
expressional pattern of CAV1 in the primary tumor-
associated stroma was analyzable for 147 primary lung can-
cer cases. CAV1 expression in the stromal cells surrounding
the tumors revealed positive expression in 63.9% patients
(Table 1). Of the positive cases, 35.4% had a strong staining,
and 28.5% had a weak staining of the stromal cells. Represen-
tative examples are shown in Figure 1.
Statistical analyses showed a significant association
between level of stromal CAV1 in primary tumors with the
histological type (p < 0 01). SCC showed frequently high
levels of stromal CAV1 expression (50.7%), whereas in AC
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Table 1: Correlation between caveolin-1 expression in lung cancer stroma and clinical parameters.
Total Negative Weak Strong
p value
n n % n % n %
All 147 53 36.1 42 28.5 52 35.4
Sex 0.25
Female 27 6 22.2 9 33.3 12 44.5
Male 120 47 39.2 33 27.5 40 33.3
Age 0.79
<MW 59 22 37.3 18 30.5 19 32.2
>MW 83 30 36.1 22 26.5 31 37.4
n.a. 5
Histology <0.01
SCC 69 17 24.6 17 24.7 35 50.7
AC 53 29 54.7 16 30.2 8 15.1
LCLC 9 3 33.3 1 11.1 5 55.6
Others 16 4 25.0 8 50.0 4 25.0
Grade combined 0.79
G1 + 2 66 22 33.3 21 31.8 23 34.9
G3+ 4 73 28 38.4 20 27.4 25 34.2
n.a. 8
Tumor size 0.17
pT1 30 10 33.3 13 43.4 7 23.3
pT2 86 31 36.1 21 24.4 34 39.5
pT3 21 9 42.9 3 14.2 9 42.9
pT4 8 3 37.5 4 50.0 1 12.5
n.a. 2
Lymph node status 0.09
pN0 76 32 42.1 22 29.0 22 28.9
pN1 41 9 22.0 15 36.6 17 41.4
pN2+ 3 28 12 42.9 4 14.3 12 42.9
n.a. 2
Distant metastasis 0.26
pM0 136 47 35.6 39 28.7 50 36.7
pM1 9 5 55.6 3 33.3 1 11.1
n.a. 2
UICC stage 0.10
IA+ B 70 29 41.4 21 30.0 20 28.6
IIA +B 31 6 19.4 11 35.4 14 45.2
IIIA+B 34 12 35.3 6 17.6 16 47.1
IV 9 5 55.6 3 33.3 1 11.1
n.a. 3
Death 0.74
No 37 12 32.4 10 27.0 15 40.6
Yes 107 40 37.4 31 29.0 36 33.6
n.a. 3
Smoking 0.99
Current 66 23 34.9 20 30.3 23 34.8
Ex-smoker 63 24 38.1 20 31.7 19 30.2
Never 3 1 33.3 1 33.3 1 33.3
n.a. 15
3Analytical Cellular Pathology
only, 15.1% of the sample showed high amounts of stromal
CAV1 (Table 1). Also, patients with a large-cell lung cancer
tumor showed a high stromal CAV1 expression (55.6%).
Stromal CAV1 expression was not associated with any other
clinicopathological factor (Table 1) even when the histologi-
cal subtypes were analyzed separately (data not shown). No
significant correlation between the expression levels of
stromal CAV1 in primary tumors and overall survival as well
as patient’s outcome could be found (data not shown).
3.2. Caveolin 1 Expression in the Stroma of Lymph Node
Metastasis. The CAV1 expression in stromal cells was also
analyzed in 39 lymph node metastases samples. 29 patients
(74.4%) showed no expression of CAV1 in stromal cells of
the lymph nodes and 10 samples (25.6%) harbored a positive
staining for CAV1. Expression of CAV1 in tumor-associated
stroma and corresponding lymph node metastasis associated
stroma (n = 32) showed concordance in 53.1% of the cases
(n = 17) (Table 2). Two negative tumor sample showed a
Table 1: Continued.
Total Negative Weak Strong
p value
n n % n % n %
Asbestos exposure 0.18
Exposed 42 20 47.6 10 23.8 12 28.6
Nonexposed 90 28 31.1 30 33.3 32 35.6
n.a. 15













Figure 1: Immunohistochemical staining for CAV1 (a–c) and CAV 2 (d–f) on lung cancer tissue samples. (a + d) Negative staining of
stromal cells and positive staining of tumor cells in squamous cell lung cancer patients. (b + e) Weak staining of stromal and negative
staining of tumor cells in adenocarcinoma patients. (c + f) Strong positive staining of stromal cells and negative staining of tumor cells in
neuroendocrine tumors.
Table 2: Correlation between expressions of caveolins in tumor-
associated stroma and corresponding lymph node metastasis-
associated stroma.
CAV1 CAV2
LN stroma∗ LN stroma∗∗
neg pos neg pos
PT stroma
neg 12 2 10 2
pos 13 5 15 12
∗p value = 0.003; ∗∗p value = 0.001.
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Table 3: Correlation between caveolin-2 expression in lung cancer stroma and clinical parameters.
Total Negative Weak Strong
p value
n n % n % n %
All 150 35 23.3 46 30.7 69 46.0
Sex 0.41
Female 25 6 24 5 20 14 56
Male 125 29 23 41 33 55 44
Age 0.60
<MW 73 20 27 21 29 32 44
>MW 74 15 20 23 31 36 49
n.a. 3
Histology 0.36
SCC 70 13 19 21 30 36 51
AC 59 14 24 22 37 23 39
LCLC 10 4 40 1 10 5 50
Others 11 4 26 2 18 5 45
Grade combined 0.57
G1 + 2 66 13 20 19 29 34 52
G3 + 4 75 18 24 25 33 32 43
n.a. 9
Tumor size 0.86
pT1 28 7 25 8 29 13 46
pT2 90 20 22 28 31 42 47
pT3 22 6 27 5 23 11 50
pT4 8 2 25 4 50 2 25
n.a. 2
Lymph node status 0.84
pN0 75 17 23 24 32 34 45
pN1 45 11 24 11 24 23 51
pN2+ 3 27 6 22 10 37 11 41
n.a. 3
Distant metastasis 0.76
pM0 137 32 23 42 31 63 46
pM1 10 3 30 2 20 5 50
n.a. 3
UICC stage 1.00
IA+ B 68 16 24 21 31 31 46
IIA +B 36 8 22 11 31 17 47
IIIA +B 33 8 24 10 30 15 46
IV 10 3 30 2 20 5 50
n.a. 3
Death 0.61
No 36 7 19 13 36 16 45
Yes 110 28 26 31 28 51 46
n.a. 4
Smoking 0.57
Current 66 19 29 15 23 32 49
Ex-smoker 66 16 24 22 33 28 42
None 3 0 0 1 33 2 67
n.a. 15
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high expression in the stromal lymph node cells whereas
40.6% (n = 13) samples with an expression in the stromal
tumor cells showed no expression in the lymph nodes, indi-
cating that CAV1 is less often expressed in the corresponding
stromal tissue of the lymph nodes (p = 0 003) (Table 2).
3.3. Stromal Caveolin 2 Expression in Primary Tumors and
Lymph Node Metastasis. The stromal CAV2 expression was
evaluable in 150 in primary lung cancer tissues. Analyses
for CAV2 expression in stromal cells of the tumors revealed
a positive expression in 115 patients (76.7%) and negative
expression in 35 patients (23.3%) (Table 3). Of the positive
cases, 46 samples (30.7%) showed a weak staining, and 69
(46.0%) showed a strong staining. Representative examples
are shown in Figure 1. Similar to CAV1, the expression of
stromal CAV2 around or within the primary tumor cells
did not show any correlation with clinical parameters includ-
ing survival. As we originally found an association of CAV2
expression in the tumor tissue [4], we also combined the
results from tumor and stromal expression. No survival
benefits could be detected for any group (data not shown).
Stromal CAV2 was expressed in 15 lymph node samples
(34.8%) whereas 28 samples showed no expression (65.1%).
Interestingly, 75.0% (n = 27) of the patients that died during
the study period had no CAV2 expression in the stroma of
lymph node metastases, whereas 83.3% of the patients who
were still alive were positive for CAV2 (p = 0 011). Compar-
ison between the expression of stromal CAV2 of matched
tumor and lymph node metastasis samples (n = 39) showed
a concordance in 56.4% (n = 22) (Table 2). Two negative
tumor samples exhibit a staining of the stroma surrounding
the lymph node metastasis, whereas 15 (38.4%) samples with
a positive staining for CAV2 in the tumor stroma showed no
staining in the stroma of lymph node metastasis (p = 0 001),
indicating a downregulation of stromal CAV2 in the metasta-
tic lymph nodes.
4. Discussion
Caveolins are known to play an important role in tumor
initiation and progression. Several publications have already
investigated the association between caveolin expression in
primary and metastatic lung tumor tissue and cancer
outcome [35–44]. In the last decades, it was shown that the
cancer stroma has an important influence on tumor behav-
ior. Whereas in the tumor tissue, high caveolin expression
has usually been associated with a poor outcome; also, in
other tumor entities, the inverse association has been found
in cancer-associated stromal tissue [15–25].
In this study, we showed that the expression of CAV1 and
CAV2 is deregulated in stromal cells of the primary tumor as
well as in the stroma of lymph nodes. For both CAV1 and
CAV2, a large heterogeneity in the stromal expression levels
was found between different samples. Whereas some patients
were totally negative for caveolins, other patients showed a
very intensive stromal caveolin expression. However, no
association to any clinical factor could be found for the
caveolin expression in the primary tumor stroma, which is
in contrast to many other tumor entities. In contrast to our
current study, Bertino et al. investigated late-stage patients
with poor prognosis and reported that high CAV1 stromal
expression in mainly squamous cell lung cancer patients
was associated with improved overall survival [42]. The study
of Onion et al. demonstrated also that high stromal CAV1 is
associated with improved overall survival in operable NSCLC
patients [45]. Shimizu et al. on the other hand manifested the
correlation between the stromal CAV1 expression in stage I
lung AC and shorter recurrence-free survival [46]. We inves-
tigated mostly early-stage patients with fairly good prognosis
but did not find any correlation.
Interestingly, we found in matched primary and lymph
node metastases tissue a significant reduction of caveolin
expression in the lymph node stroma, indicating that during
the metastatic progression stromal caveolin could be lost and
thus supporting the finding of a negative association between
loss of caveolins and bad prognosis. The functional role of
caveolin expression in the tumor stroma is still not clearly
understood. Loss of caveolins in the stromal cells could be
regulated by signals from metastatic tumor cells to enable
the tumor cells to escape the growth-suppressing properties
of the stroma and convert the normal fibroblast to cancer-
associated fibroblasts (CAFs). Indeed, silencing of CAV1 in
fibroblasts has been shown to induce the conversion of
benign stromal fibroblasts to CAFs by the TGF-β pathway
[22, 47, 48]. Furthermore, Bonuccelli et al. showed in a breast
cancer mouse model that Cav-1-deficient stromal fibroblasts
upregulate the expression of glycolytic enzymes, a hallmark
of the Warburg effect, and this may provide energy-rich
metabolites in a paracrine fashion to the tumor cells,
supporting the clinical findings in breast cancer [49]. In lung
cancer, however, the potential role of stromal caveolin
expression as predictive and prognostic markers needs
clearly still to be assessed in further larger studies combined
with functional analyses.
Table 3: Continued.
Total Negative Weak Strong
p value
n n % n % n %
Asbestos 0.28
No 84 22 26 20 24 42 50
Yes 47 12 26 17 36 18 38
n.a. 19
n.a.: not available; ex-smoker: quit smoking > 6months prior to surgery.
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